ArticleInvestigational new drugs2025

Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors.

Roger B Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.